HealthTech Pioneer myTomorrows Lands $29M to Boost Global Patient Access
November 12, 2025, 9:37 pm
myTomorrows, a Dutch HealthTech innovator, just secured a $29 million investment from Avego. This capital injection propels its global mission. The company bridges the critical gap between emerging therapies and patients in need. Its AI-driven platform connects patients, physicians, and BioPharma. It simplifies access to pre-approval treatments, including clinical trials and expanded access programs. This funding will accelerate international expansion and platform development. It also aims to shorten clinical timelines and gather real-world data. myTomorrows has already aided over 16,900 patients across 133 countries. It tackles the urgent challenge of 300 million patients without approved options, linking them to over 10,000 therapies in development. This move promises more equitable and swift access to tomorrow's medicines worldwide.
MyTomorrows, a leading HealthTech firm, is redefining global healthcare access. The company recently secured a significant $29 million investment. Avego’s growth equity fueled this capital injection. This funding targets a vital mission: expanding access to pre-approval treatments worldwide.
Many patients face severe conditions. Approved treatment options often do not exist for them. Yet, scientific advancement progresses rapidly. Thousands of new therapies are constantly under development. MyTomorrows bridges this critical divide. It connects patients to promising investigational therapies. These include both clinical trials and expanded access programs (EAPs).
The investment from Avego empowers myTomorrows. It will accelerate the company's international growth. The AI-driven global platform will see further enhancement. This means better integration with BioPharma partners. It promises shorter clinical development timelines. Real-world evidence generation will improve. Regulatory insights will strengthen.
MyTomorrows operates a unified, multi-stakeholder platform. It uses artificial intelligence. Human expertise complements the AI. This combination simplifies treatment discovery. It provides transparency and coordination. Patients, physicians, trial sites, and BioPharma partners all connect. This ecosystem approach streamlines access. It advances data-driven drug development.
The scale of the problem is immense. Over 300 million patients globally lack approved treatment options. Simultaneously, more than 10,000 therapies are in development. MyTomorrows directly addresses this urgent challenge. Its platform empowers patients. Clinicians also benefit from expert guidance. Personalized treatment matching becomes possible. Seamless access to trials and EAPs follows.
For BioPharma partners, myTomorrows offers comprehensive services. These include efficient trial recruitment. Expanded access program management is crucial. Real-world data capture supports research. Trial sites also gain advantages. They utilize unified referral systems. Real-time tracking and enhanced visibility are key features.
MyTomorrows has already demonstrated substantial global impact. The platform has supported over 16,900 patients. This reach extends across 133 countries. The company operates from its Amsterdam headquarters. It also maintains a strategic office in New York City. This dual presence supports its worldwide mission.
The company's vision extends far beyond current capabilities. This new funding marks a pivotal step. MyTomorrows aims to provide equitable access to emerging therapies. Every patient, regardless of location, deserves a fair chance. Avego’s deep life sciences expertise provides critical support. Its BioPharma insights will be instrumental for scaling the platform.
The HealthTech landscape is dynamic. MyTomorrows' funding round stands out. It signals strong investor confidence. Solutions bridging early-stage drug development and patient access are highly valued. Other European HealthTech companies also saw significant investments in 2025. Sequana Medical secured €24 million. ArcaScience raised €6 million. CurifyLabs obtained €6.7 million. These companies operate in related segments. MyTomorrows, however, specializes in patient access to pre-approval therapies. Its AI-enabled platform makes it unique.
The journey began in 2012. MyTomorrows was founded with a clear goal. Connect patients with promising therapies more effectively. This vision complements traditional drug development. It expands innovation access. The latest investment signifies a new phase. It promises accelerated growth and expanded global impact.
MyTomorrows lays the foundation for a new era in global healthcare. This era will be defined by AI-enabled precision. Adaptive regulation will be key. Empowered patients stand at the center. The platform integrates across health systems globally. It provides unbiased, actionable pathways. These pathways lead to emerging therapies. Medical breakthroughs reach those in need. They arrive precisely when it matters most. This is the future of treatment access.
MyTomorrows, a leading HealthTech firm, is redefining global healthcare access. The company recently secured a significant $29 million investment. Avego’s growth equity fueled this capital injection. This funding targets a vital mission: expanding access to pre-approval treatments worldwide.
Many patients face severe conditions. Approved treatment options often do not exist for them. Yet, scientific advancement progresses rapidly. Thousands of new therapies are constantly under development. MyTomorrows bridges this critical divide. It connects patients to promising investigational therapies. These include both clinical trials and expanded access programs (EAPs).
The investment from Avego empowers myTomorrows. It will accelerate the company's international growth. The AI-driven global platform will see further enhancement. This means better integration with BioPharma partners. It promises shorter clinical development timelines. Real-world evidence generation will improve. Regulatory insights will strengthen.
MyTomorrows operates a unified, multi-stakeholder platform. It uses artificial intelligence. Human expertise complements the AI. This combination simplifies treatment discovery. It provides transparency and coordination. Patients, physicians, trial sites, and BioPharma partners all connect. This ecosystem approach streamlines access. It advances data-driven drug development.
The scale of the problem is immense. Over 300 million patients globally lack approved treatment options. Simultaneously, more than 10,000 therapies are in development. MyTomorrows directly addresses this urgent challenge. Its platform empowers patients. Clinicians also benefit from expert guidance. Personalized treatment matching becomes possible. Seamless access to trials and EAPs follows.
For BioPharma partners, myTomorrows offers comprehensive services. These include efficient trial recruitment. Expanded access program management is crucial. Real-world data capture supports research. Trial sites also gain advantages. They utilize unified referral systems. Real-time tracking and enhanced visibility are key features.
MyTomorrows has already demonstrated substantial global impact. The platform has supported over 16,900 patients. This reach extends across 133 countries. The company operates from its Amsterdam headquarters. It also maintains a strategic office in New York City. This dual presence supports its worldwide mission.
The company's vision extends far beyond current capabilities. This new funding marks a pivotal step. MyTomorrows aims to provide equitable access to emerging therapies. Every patient, regardless of location, deserves a fair chance. Avego’s deep life sciences expertise provides critical support. Its BioPharma insights will be instrumental for scaling the platform.
The HealthTech landscape is dynamic. MyTomorrows' funding round stands out. It signals strong investor confidence. Solutions bridging early-stage drug development and patient access are highly valued. Other European HealthTech companies also saw significant investments in 2025. Sequana Medical secured €24 million. ArcaScience raised €6 million. CurifyLabs obtained €6.7 million. These companies operate in related segments. MyTomorrows, however, specializes in patient access to pre-approval therapies. Its AI-enabled platform makes it unique.
The journey began in 2012. MyTomorrows was founded with a clear goal. Connect patients with promising therapies more effectively. This vision complements traditional drug development. It expands innovation access. The latest investment signifies a new phase. It promises accelerated growth and expanded global impact.
MyTomorrows lays the foundation for a new era in global healthcare. This era will be defined by AI-enabled precision. Adaptive regulation will be key. Empowered patients stand at the center. The platform integrates across health systems globally. It provides unbiased, actionable pathways. These pathways lead to emerging therapies. Medical breakthroughs reach those in need. They arrive precisely when it matters most. This is the future of treatment access.